PGIC assessment (evaluable population) at week 24 by dosing arm. Number of patients with any improvement in disease symptoms was greatest at 200 mg twice per day (n = 18) compared with lower doses (100 mg once per day, n = 10; 100 mg twice per day, n = 13).